Spinal Muscular Atrophy Indication Strategy Report 2026: SMN2, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Frontotemporal Dementia Indication Strategy Report 2026: PGRN, Tau, TDP-43 and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Huntington's Disease Indication Strategy Report 2026: HTT-Lowering, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

ALS Indication Strategy Report 2026: SOD1, TDP-43, Trials and Deal Landscape uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Parkinson's Disease Indication Strategy Report 2026: α-Synuclein, LRRK2, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Diabetic Gastroparesis Indication Strategy Report 2026: Motilin, 5-HT4, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Acute Pancreatitis Indication Strategy Report 2026: Trypsin, NLRP3, Trials and Market Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Chronic Pancreatitis Indication Strategy Report 2026: CFTR, PRSS1, Pain Trials and Whitespace uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Sarcopenia Indication Strategy Report 2026: Myostatin, ACVR2B, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Osteoarthritis Indication Strategy Report 2026: NGF, ADAMTS5, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Osteoporosis Indication Strategy Report 2026: RANKL, Sclerostin, Trials and 46 Deal Signals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Hypoparathyroidism Indication Strategy Report 2026: PTH1R, CaSR, Phase 3 Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.